XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy

Abstract Many recent publications highlight the large role of the pivotal eukaryotic nuclear export protein exportin-1 (XPO1) in the oncogenesis of several malignancies, and there is emerging evidence that XPO1 inhibition is a key target against cancer. The clinical validation of the pharmacological...

Full description

Bibliographic Details
Main Authors: Vincent Camus, Hadjer Miloudi, Antoine Taly, Brigitte Sola, Fabrice Jardin
Format: Article
Language:English
Published: BMC 2017-02-01
Series:Journal of Hematology & Oncology
Subjects:
XPO1
Exportin
Lymphoma
Targeted therapy
Minimal residual disease
Online Access:http://link.springer.com/article/10.1186/s13045-017-0412-4

Internet

http://link.springer.com/article/10.1186/s13045-017-0412-4

Similar Items